BD (Becton, Dickinson and Company) and Ypsomed are strengthening an existing collaboration with a new version of a glass prefillable syringe.

The 5.5mL version of the BD Neopak XtraFlow syringe is fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform. Accordingly, it expands options for pharmaceutical companies, and patients requiring large-volume, subcutaneous self-injections.

YpsoMate was first introduced in 2022. Among its features are an ergonomic design, two-step activation, and clear feedback. The last of these, Ypsomed says, supports patient confidence and ease of use.

Syringe Adjusts to Biologics Needs

By definition, large-volume subcutaneous biologics injections are greater than 1 mL. Increasingly, they are common in treatments for oncology, autoimmune and rare diseases, and metabolic disorders.

In support of this, the new BD syringe has a shorter (8mm) needle and thinner wall cannulas. This in turn facilitates delivery of higher volume and viscosity medicines.

Ideally, BD and Ypsomed said, such enhancements enable improved injection time and optimized flow. These can be common challenges in large-volume biologics.

BD, Ypsomed Leaders React

In response to this latest collaboration, both companies touted the benefits of the new syringe.

“This next-generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “By combining BD’s expertise in drug delivery with Ypsomed’s leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions.”

“Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity,” said Ulrike Bauer, Ypsomed Chief Business Officer. “These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery.”